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Abstract
Background: Golestan Province, at the western end of the Asian esophageal cancer (EC) belt in northeastern Iran, was reported to have 
one of the highest worldwide rates of EC in the 1970s. We have previously shown a declining incidence of EC in Golestan during the last 
decades. This study reports additional new results from the Golestan Population-based Cancer Registry (GPCR).
Methods: The GPCR collected data from newly diagnosed (incident) cancer cases from all 68 public and private diagnostic and thera-
peutic centers in Golestan Province. CanReg-4 software was used for data entry and analysis based on the guidelines of the International 
Agency for Research on Cancer (IARC). Age-standardized incidence rates (ASR) of cancers were calculated using the 2000 world standard 
population.
Results: From 2004 through 2008, 9007 new cancer cases were reported to the GPCR. The mean (SD) age was 55.5 (18.6) years, and 
54% were diagnosed in men. The ASRs of all cancers were 175.3 and 141.1 per 100,000 person-years for males and females, respectively. 
Cancers of the stomach (ASR:30.7), esophagus (24.3), and lung (15.4) were the most common cancers in males. In females, breast cancer 
(ASR:26.9) was followed by malignancies of the esophagus (19.1) and stomach (12.4). The diagnosis of cancer was based on histopatho-
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Conclusions: The EC incidence rate continues to decline in Golestan, while the incidence rates of stomach, colorectal, and breast can-
cers continue to increase.
Cite the article as: Roshandel G, Sadjadi A, Aarabi M, Keshtkar A, Sedaghat SM, Nouraie SM, Semnani S, Malekzadeh R. Cancer Incidence in Golestan Province: 
Report of an Ongoing Population-based Cancer Registry in Iran, 2004–2008. Arch Iran Med. 2012; 15(4): 196 – 200.
Introduction
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			cancer diagnoses to the Iranian Ministry of Health (IMOH).1 
Iranian health authorities have maintained a pathology-
based cancer registry since 1986.2			
which includes at maximum 80% of the new cancer cases, was 
published recently.3 The Digestive Diseases Research Center 
(DDRC) of Tehran University of Medical Sciences (TUMS) has 
established population-based cancer registries in two northern 
provinces of Iran, Ardabil, and Golestan, in collaboration with the 
International Agency for Research on Cancer (IARC), the Center 
for Disease Control at IMOH and local medical universities.4 
Golestan Province is located at the southeastern corner of the Cas-
pian Sea (northeast Iran), at the western end of the Asian esopha-
geal cancer (EC) belt.5 It is located in the steppe grasslands of the 
Turkmen plain and neighboring hills6 and includes Turkmen 
(35%) and Fars (65%) ethnic groups. Historically, the incidence 
of EC was found to be very high in this region.7 Mahboubi et al. 
in 1973 reported exceptionally high age-adjusted incidence rates 
(up to 165.5/100,000 in men and 195.3/100,000 in women) for 
EC in this region.6 
The Golestan Population-based Cancer Registry (GPCR) began 
	
				-
cer surveillance for 1996 to 2000, published in 2006. This study 
showed a declining incidence of EC and an increasing incidence 
of gastric, colorectal, and breast cancers in this region compared 
to the data published from this area in the 1970s.8 GPCR is now 
run by the Golestan Research Center of Gastroenterology and 
Hepatology (GRCGH) of Golestan University of Medical Sci-
ences (GOUMS), under the supervision of DDRC/TUMS.  Since 
January 2006, all data in the GPCR was collected prospectively, 
and the GPCR has been a member of the International Association 
of Cancer Registries (IACR) since 2007. In this report, we pres-
ent cancer incidence data collected by the GPCR over the 5-year 
period from 2004 through 2008.
Materials and Methods
GPCR collected information on newly diagnosed (incident) can-
cer cases from all public and private diagnostic and therapeutic 
centers in Golestan Province, including hospitals, pathology/labo-
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ratory centers, imaging centers and some specialist physicians’ 
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	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'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mation from medical centers and regional registries in the neigh-
boring provinces, particularly Khorasan Razavi, Mazandaran, and 
Tehran, to minimize loss of data for Golestan residents who were 
diagnosed in other provinces. Data was collected both actively 
and passively by well-trained registry staff that regularly visited 
all centers and collected information on cancer cases. GPCR also 
regularly received information on cancer-related deaths from the 
death registry at the health department of GOUMS and matched 
				
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GPCR registered only primary cancers; secondary tumors re-
sulting from the invasion or metastasis of primary cancers were 
excluded from this report. Malignant tumors of all organs were 
registered based on IARC standards.9
10% of data collection forms were checked and compared with 
the original documents in the source centers to verify the accu-
racy and completeness of the abstraction process. The results of 
this checking process were acceptable in the majority of centers. 
   *		"			
for Oncology (ICD-O-III) was used to code the anatomical site 
and histology of the tumors.10 IARC multiple primary rules11 were 
used for patients with malignant tumors of more than one site.
Cases reported to GPCR were initially checked for duplications 
before entry into the database.12 This duplication check included 

		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 	
	
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name, topography of tumor, place of residence, and year of diag-
nosis. The Persian version of CanReg4 software was used for data 
entry, and the data was checked with the IARC check program.12
Incidence rates were age-adjusted to the 2000 world standard 
population in 18 age categories of 5 years each (0–4, 5–9..., 
85+), and expressed per 100,000 population. Information about 
the Golestan population in 2006 was obtained from the provin-
cial census done by the Health Department of GOUMS. Figure 
1 shows the population pyramid of Golestan in 2006. We used 
Segi’s method to calculate the age-standardized incidence rates 
(ASRs) per 100,000 person-years for all cancers as well as the 
truncated (34–65 years) ASR (TASR) of EC.13 P-values of less 
X				
The protocol was approved by the Ethics Committee of GOUMS 
""Y*	YZ*
-
sures were used to ensure the preservation of anonymity of the 
cancer cases, the best quality of registry data, and the best possible 
usage of the data.9,14
Results
During the 5-year period from 2004 through 2008, 9007 new 
cancer cases were reported to GPCR from 68 healthcare centers 
across the province, the provincial death registry, and medical 
centers and cancer registries in neighboring provinces. More than 
half, 4862 (54%), of the cases were male (male to female ratio = 
1.2; P\LB]^		`]{
'	-
{
'|
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
The other methods of diagnosis were DCO in 9%, clinical in 10%, 
and para-clinical (e.g., imaging studies or surgical reports) in 10% 
of cases. The overall ASRs for all cancers were 175.3 (95% CI: 
166.5–184.5) and 141.1 (95% CI: 133.2–149.5) per 100,000 per-
son-years in males and females, respectively. Male patients were 
generally older than female patients, with median (inter-quartile 
range) ages of 62 (48-73) and 53 (41-66) years, respectively (P 
= 0.001).
!	?!}L	^{
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females are shown in Table 1.  Table 2 shows several indices of 
data quality for GPCR data collected between 2004 and 2008. The 
MV% increased from 60% in 2004 to 75% in 2008, with a con-
comitant decline in the DCO% from 23% in 2004 to 5% in 2008. 
The proportion of cases with an unknown primary site decreased 
from 6% in 2004 to 2% in 2008. There were no cases with an 
unknown method of diagnosis or an unknown age or sex in the 
GPCR between 2004 and 2008.
Table 3 shows the case numbers, crude rates and ASRs of the 
ten most common cancers in each sex. Stomach and esophageal 
malignancies were the most common cancers in males, while 
Figure 2. Previous* (1970s) and current divisions of Golestan Province, Iran (*Refer-
ence 6).
Figure 1. Population pyramid of Golestan Province, 2006. 
(Source: Health Department of Golestan University of Medi-
cal Sciences)
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breast and esophageal cancers were the most common tumors in 
females.
Table 4 shows the ASRs and TASRs (34–65 years) of EC in 
the different regions of Golestan Province (Figure 2) reported in 
1968–1971 and in the current Cancer Registry data. The incidence 
rate of EC was higher in Gonbad and Kalaleh districts, located in 
the eastern area of the province, than in the other districts at both 
time points, both in males and in females.  Between 1968–1971 
 +=  	  	 *Y	 -
clined 57%–82%.
Discussion
The Golestan Population-based Cancer Registry showed im-
provement in several quality measures during 2004–2008 (Table 
L  	  		  
	  -
creased from 60% to 75% and the cases diagnosed only by death 
	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
2006 on, all data has been collected prospectively. Indices of data 
quality are now within acceptable ranges according to IARC stan-
dards,11			*Y	-
tion-based cancer registry by these standards.
The incidence of cancers was higher in males than in females, 
which is in agreement with the results of most other cancer regis-
tries.3,11,15 The mean age for cancer cases in our study (55.5 years) 
was similar to other reports from Iran.15,16
According to this study, the ASRs of cancer in Golestan Prov-
ince were 175.3 for males and 141.1 for females, which were 
	
	'		
in Iran.17 A recent pathology-based National Cancer Registry from 
Sex Location MV%
Male
Stomach 68
Esophagus 73
Trachea, bronchus, lung 29
Hematopoietics 98
Colorectal 74
Female
Breast 75
Esophagus 73
Stomach 64
Hematopoietic 100
Colorectal 73
Table 1.		
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Iran (2004–2008).
2004 2005 2006 2007 2008
Total population 1592989 1614376 1640200 1668561 1693165
Number of cancer cases 1513 1709 1851 1937 1997
ASR of all cancers-male 156 177 187 172 174
ASR of all cancers -female 118 130 149 151 150
!	?{L 60 70 71 74 75
"?{L 23 11 8 6 5
Unknown primary site (%) 6 2 1 2 2
Unknown method of diagnosis (%) 0 0 0 0 0
Unknown age (%) 0 0 0 0 0
Unknown sex (%) 0 0 0 0 0
ASR: Age standardized incidence rates (per 100000 person-years).
Table 2. Trend of data quality indices in Golestan Population-based Cancer Registry (GPCR), 2004–2008.
Male Female
Organ Number of cases Crude rate ASR Organ Number of cases Crude rate ASR
Stomach 793 19.17 30.7 Breast 886 21.80 26.9
Esophagus 622 15.04 24.3 Esophagus 478 11.76 19.1
Lung 405 9.79 15.4 Stomach 325 8.00 12.4
Colorectal 345 8.34 12.4 Colorectal 266 6.54 9.5
Leukemia 338 8.17 10.5 Leukemia 238 5.86 7.4
Skin 324 7.83 12.6 Skin 207 5.09 8.2
Prostate 267 6.46 10.1 Ovary 187 4.60 5.7
Lymphoma 263 6.36 7.6 Nervous system 165 4.06 5.3
Nervous system 242 5.85 7.2 Lymphoma 161 3.96 4.7
Bladder 222 5.37 8.7 Lung 160 3.94 5.9
Total: All sites 4862 117.55 175.3 Total: All sites 4145 101.97 141.1
All sites, except skin 4561 110.27 163.8 All sites except skin 3953 97.25 133.6
Table 3. Case numbers, crude incidence rates and age-standardized incidence rates (ASR) per 100,000 persons-years of the top ten cancers in 
Golestan Province, Iran (2004–2008).
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IMOH, on the other hand, has underestimated the incidence of 
cancer in Golestan (reporting ASRs of cancers for Golestan as low 
as 61 in males and 54 in females)3 and other parts of the country. 
This is most likely due to the different methodologies of the two 
registries: the only data source for the IMOH registry is pathology 
reports, and all data is collected passively, which are well-known 
shortcomings of this type of registry. Therefore, it is highly rec-
ommended that national cancer incidence and mortality rates be 
estimated based on population-based cancer registries with active 
case ascertainment, as they were estimated in the past.18
Stomach and esophageal cancers were the most common can-
cers in Golestan males during this time period. These results are 
similar to reports from some other Asian countries.19 The most 
frequent female cancers in Golestan Province were breast and 
			
		'20 
Babaei et al. also reported breast cancer to be the most common fe-
male cancer in Semnan Province, although this site was followed 
in frequency by cancers of the uterus and ovary.16 In contrast, in 
Yemen, another country in the region, the most frequent cancers 
in males were leukemia and lymphoma, and the most common 
malignancies in females were breast cancer and leukemia.21 As 
incidence rates and common causes of cancers show considerable 
variation between countries and even between different regions 
of the same country, cancer control programs need to be planned 
		
We found an increasing trend in the incidence of cancer in both 
males and females between 2004 and 2006 (Table 2). The most 
likely explanation for this trend is that the cancer cases in 2004 
and 2005 were registered retrospectively, and underestimation is 
an important limitation of retrospective data collection. The pro-
spective phase of the GPCR was started since 2006, and our re-
					

2006 to 2008.
We found a decreasing trend in EC rates and increasing trends 
in the incidence of colorectal, breast and lung cancers and leuke-
mia when compared to previous reports from this area.6,8 These 
changing rates may be partly due to the adoption of a western 
type lifestyle in Golestan during the last 20 years. The decreasing 
trend of EC, which has been reported previously,8	

in this study. Recent epidemiological studies in the Turkmen plain 
of Iran by our group have shown that alcohol and tobacco are not 
the main risk factors for EC in this area.22 Other risk factors, such 
as socioeconomic status, drinking hot tea, opium consumption, 
poor oral health, and drinking non-piped water, are probably more 
important in the etiology of EC in Golestan.22–25 One major rea-
son for declining EC rates in this area is the overall improvement 
in socioeconomic status, including higher incomes, availability 
of electricity, access to safe drinking water, natural gas for heat-
ing and cooking, television, telephone communication and public 
transport in 98% of the urban areas and 92% of the rural areas in 
today’s Golestan.26,27
Table 4 compares the current incidence rates of EC in the differ-
ent regions of Golestan Province (Figure 2) with the rates reported 
during the 1970s.6 Despite the striking 57% - 82% drop in ASRs, 
the geographical distribution of EC in the present study was simi-
lar to that of the previous report.6 For example, the incidence rate 
of EC was considerably higher in Gonbad and Kalaleh (regions 
6a and 6b in the previous report) in both the current and previ-
ous studies.6 Thus, despite its overall declining trend, EC remains 
a major health problem in this part of Golestan Province, which 
needs further investigation to determine unknown risk factors. In 
addition, implementation of an EC control program may be ben-
	
In conclusion,*Y	'	*-
cer Registry based on IARC standards, and a major asset for plan-
ning cancer prevention strategies in this province. It may also 
be considered a good model for establishing population-based 
Cancer Registries in other provinces of Iran and in other Middle 
Eastern countries. Similar to our previous report,8 we have found 
that the EC incidence rate continues to decline in Golestan, while 
the rates of stomach, colorectal, and breast cancers continue to 
increase.  
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Previous study† 
1968–1971
GPCR* 
2004–2008
Male Female Male Female
ASR TASR ASR TASR ASR TASR ASR TASR
Region A¶ 53.8 104.1 38.7 92.7 14.9 34.4 12.7 30.9
Region B¶ 83.7 173.7 76.9 185.4 18.1 72.1 13.6 39.4
Region C¶ 81.3 151.6 59.6 128.1 21.5 68.5 23.3 70.9
Region D¶ 96.6 217.7 137.7 334.9 37.5 126.4 27.3 84.8
Region E¶ 165.5 515.6 195.3 480.7 70.7 193.7 42.6 140.4
* Golestan Population-based Cancer Registry
† Reference 6
¶ Refer to Figure 2
Table 4. Age standardized incidence rates (ASR) and truncated (34–65 years) ASR (TASR) for esophageal cancer (EC) in different regions of 
Golestan Province, Iran in 1968-1971 and 2004–2008.
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